DAPA-MI: Cardiometabolic Endpoints 'Win' With Dapagliflozin After Acute MI

(UPDATED) The trial had to switch out its hard primary endpoints for a win-ratio analysis: the result was a “soft positive,” one observer said.

Related Keywords

United States ,Sweden ,New York ,Uppsala ,Uppsala Lan ,Philadelphia ,Pennsylvania ,United Kingdom ,American ,Los Angeles ,Jonas Oldgren ,Carlos Santos Gallego ,Michelle Kittleson ,Stefan James ,Phd Uppsala University ,Novartis ,American Heart Association ,Astrazeneca ,Uppsala University ,Icahn School ,Mount Sinai ,